In vivo and in vitro protective effects of pentamethylquercetin on cardiac hypertrophy

Cardiovascular Drugs and Therapy

Volumn 26, Issue 2, 2012, Pages 109-120

  He, Ting ^a   Chen, Lei ^a   Chen, Yong ^b   Han, Yi ^a   Yang, Wei Qin ^a   Jin, Man Wen ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cardiac fibrosis; Cardiac hypertrophy; Inflammation; Pentamethylquercetin; PPAR ? and PPAR ; Pressure overload

Indexed keywords

ALDOSTERONE; BRAIN NATRIURETIC PEPTIDE; COLLAGEN; ENDOTHELIN 1; FLAVONOID; INTERLEUKIN 6; MESSENGER RNA; PENTAMETHYLQUERCETIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ABDOMINAL AORTA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; DIASTOLIC DYSFUNCTION; DOWN REGULATION; DRUG DOSE INCREASE; DRUG STRUCTURE; FIBROBLAST; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; IN VITRO STUDY; IN VIVO STUDY; MALE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE; SYSTOLIC DYSFUNCTION; UPREGULATION;

ALDOSTERONE; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CARDIOTONIC AGENTS; CELLS, CULTURED; COLLAGEN; DOWN-REGULATION; ENDOTHELIN-1; FIBROBLASTS; FIBROSIS; HEART FAILURE; HEMODYNAMICS; INTERLEUKIN-6; MALE; MYOCYTES, CARDIAC; NATRIURETIC PEPTIDE, BRAIN; PPAR ALPHA; PPAR-BETA; QUERCETIN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84862769372     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6363-z     Document Type: Article

References (38)

1. Rohini A, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res. 2009; 61:269-80.
2. Weiss CS, Hagenmuller M, Pichler M, Munz S, Ochs M, Buss SJ, Bekeredjian R, Katus HA, Hardt SE. Activation of ppargamma by pioglitazone does not attenuate left ventricular hypertrophy following aortic banding in rats. Naunyn Schmiedebergs Arch Pharmacol. 2010;381:285-95.
3. Hellman U, Hellstrom M, Morner S, Engstrom-Laurent A, Aberg AM, Oliviero P, Samuel JL, Waldenstrom A. Parallel up-regulation of fgf-2 and hyaluronan during development of cardiac hypertrophy in rat. Cell Tissue Res. 2008;332:49-56.
4. Rathore HA, Munavvar AS, Abdullah NA, Khan AH, Fathihah B, NurJannah MH, Raisa NA, Anand Swarup KR, Abdullah MH, Salman IM, Johns EJ. Interaction between renin-angiotensin and sympathetic nervous systems in a rat model of pressure overload cardiac hypertrophy. Auton Autacoid Pharmacol. 2009;29:171-80.
5. Choudhary R, Palm-Leis A, Scott 3rd RC, Guleria RS, Rachut E, Baker KM, Pan J. All-trans retinoic acid prevents development of cardiac remodeling in aortic banded rats by inhibiting the reninangiotensin system. Am J Physiol Heart Circ Physiol. 2008;294: H633-44. (Pubitemid 351253274)
6. Gao S, Long CL, Wang RH, Wang H. K(atp) activation prevents progression of cardiac hypertrophy to failure induced by pressure overload via protecting endothelial function. Cardiovasc Res. 2009;83:444-56.
7. Li RW, Theriault AG, Au K, Douglas TD, Casaschi A, Kurowska EM, Mukherjee R. Citrus polymethoxylated flavones improve lipid and glucose homeostasis and modulate adipocytokines in fructose-induced insulin resistant hamsters. Life Sci. 2006; 79:365-73. (Pubitemid 44172805)
8. Takemura H, Itoh T, Yamamoto K, Sakakibara H, Shimoi K. Selective inhibition of methoxyflavonoids on human cyp1b1 activity. Bioorg Med Chem. 2010;18:6310-5.
9. Miyata Y, Sato T, Imada K, Dobashi A, Yano M, Ito A. A citrus polymethoxyflavonoid, nobiletin, is a novel mek inhibitor that exhibits antitumor metastasis in human fibrosarcoma ht-1080 cells. Biochem Biophys Res Commun. 2008;366:168-73. (Pubitemid 350297226)
10. Miyazawa M, Okuno Y, Fukuyama M, Nakamura S, Kosaka H. Antimutagenic activity of polymethoxyflavonoids from citrus aurantium. J Agric Food Chem. 1999;47:5239-44. (Pubitemid 30016968)
11. Sae-Wong C, Matsuda H, Tewtrakul S, Tansakul P, Nakamura S, Nomura Y, Yoshikawa M. Suppressive effects of methoxyflavonoids isolated from kaempferia parviflora on inducible nitric oxide synthase (inos) expression in raw 264.7 cells. J Ethnopharmacol. 2011;136:488-95.
12. Kunimasa K, Kuranuki S, Matsuura N, Iwasaki N, Ikeda M, Ito A, Sashida Y, Mimaki Y, Yano M, Sato M, Igarashi Y, Oikawa T. Identification of nobiletin, a polymethoxyflavonoid, as an enhancer of adiponectin secretion. Bioorg Med Chem Lett. 2009;19: 2062-4.
13. Miyata Y, Tanaka H, Shimada A, Sato T, Ito A, Yamanouchi T, Kosano H. Regulation of adipocytokine secretion and adipocyte hypertrophy by polymethoxyflavonoids, nobiletin and tangeretin. Life Sci. 2011;88:613-8.
14. Matsuda H, Kogami Y, Nakamura S, Sugiyama T, Ueno T, Yoshikawa M. Structural requirements of flavonoids for the adipogenesis of 3t3-l1 cells. Bioorg Med Chem. 2011;19:2835-41.
15. Park YH, Xu XR, Chiou GC. Structural requirements of flavonoids for increment of ocular blood flow in the rabbit and retinal function recovery in rat eyes. J Ocul Pharmacol Ther. 2004;20:189-200. (Pubitemid 38849800)
16. Hibasami H, Mitani A, Katsuzaki H, Imai K, Yoshioka K, Komiya T. Isolation of five types of flavonol from seabuckthorn (hippophae rhamnoides) and induction of apoptosis by some of the flavonols in human promyelotic leukemia hl-60 cells. Int J Mol Med. 2005;15:805-9.
17. Mao Z, Liang Y, Du X, Sun Z. 3, 3?, 4?, 5, 7-pentamethylquercetin reduces angiotensin ii-induced cardiac hypertrophy and apoptosis in rats. Can J Physiol Pharmacol. 2009;87:720-8.
18. Tang Y, Long CL, Wang RH, CuiW, Wang H. Activation of sur2b/ kir6.1 subtype of adenosine triphosphate-sensitive potassium channel improves pressure overload-induced cardiac remodeling via protecting endothelial function. J Cardiovasc Pharmacol. 2010;56:345-53.
19. Stewart Jr JA, Massey EP, Fix C, Zhu J, Goldsmith EC, Carver W. Temporal alterations in cardiac fibroblast function following induction of pressure overload. Cell Tissue Res. 2010;340:117-26.
20. Yan L, Huang H, Tang QZ, Zhu LH, Wang L, Liu C, Bian ZY, Li H. Breviscapine protects against cardiac hypertrophy through blocking pkc-alpha-dependent signaling. J Cell Biochem. 2010;109:1158-71.
21. Molina EJ, Gupta D, Palma J, Torres D, Gaughan JP, Houser S, Macha M. Novel experimental model of pressure overload hypertrophy in rats. J Surg Res. 2009;153:287-94.
22. Alibin CP, Kopilas MA, Anderson HD. Suppression of cardiac myocyte hypertrophy by conjugated linoleic acid: Role of peroxisome proliferator- activated receptors alpha and gamma. J Biol Chem. 2008;283:10707-15.
23. Li CB, Li XX, Chen YG, Zhang C, Zhang MX, Zhao XQ, Hao MX, Hou XY, Gong ML, Zhao YX, Bu PL, Zhang Y. Effects and mechanisms of pparalpha activator fenofibrate on myocardial remodelling in hypertension. J Cell Mol Med. 2009; 13:4444-52.
24. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009;123:255-78.
25. Shen DF, Tang QZ, Yan L, Zhang Y, Zhu LH, Wang L, Liu C, Bian ZY, Li H. Tetrandrine blocks cardiac hypertrophy by disrupting reactive oxygen species-dependent erk1/2 signalling. Br J Pharmacol. 2010;159:970-81.
26. Lee KS, Park JH, Lee S, Lim HJ, Park HY. Ppardelta activation inhibits angiotensin ii induced cardiomyocyte hypertrophy by suppressing intracellular ca2+ signaling pathway. J Cell Biochem. 2009;106:823-34.
27. Coll T, Barroso E, Alvarez-Guardia D, Serrano L, Salvado L, Merlos M, Palomer X, Vazquez-Carrera M: The role of peroxisome proliferator-activated receptor beta/delta on the inflammatory basis of metabolic disease. PPAR Res 2010;2010. pii:368467.
28. Kis A, Murdoch C, Zhang M, Siva A, Rodriguez-Cuenca S, Carobbio S, Lukasik A, Blount M, O'Rahilly S, Gray SL, Shah AM, Vidal-Puig A. Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice. Eur J Heart Fail. 2009;11:533-41.
29. Engle SK, Solter PF, Credille KM, Bull CM, Adams S, Berna MJ, Schultze AE, Rothstein EC, Cockman MD, Pritt ML, Liu H, Lu Y, Chiang AY, Watson DE. Detection of left ventricular hypertrophy in rats administered a peroxisome proliferator-activated receptor alpha/gamma dual agonist using natriuretic peptides and imaging. Toxicol Sci. 2009;114:183-92.
30. Creemers EE, Pinto YM. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc Res. 2011;89:265-72.
31. Smeets PJ, Teunissen BE, Planavila A, de Vogel-van den Bosch H, Willemsen PH, van der Vusse GJ, van Bilsen M. Inflammatory pathways are activated during cardiomyocyte hypertrophy and attenuated by peroxisome proliferator-activated receptors pparalpha and ppardelta. J Biol Chem. 2008;283:29109-18.
32. Planavila A, Iglesias R, Giralt M, Villarroya F. Sirt1 acts in association with ppar{alpha} to protect the heart from hypertrophy, metabolic dysregulation, and inflammation. Cardiovasc Res. 2010;90:276-84.
33. Palomer X, Alvarez-Guardia D, Rodriguez-Calvo R, Coll T, Laguna JC, Davidson MM, Chan TO, Feldman AM, Vazquez- Carrera M. Tnf-alpha reduces pgc-1alpha expression through nf-kappab and p38 mapk leading to increased glucose oxidation in a human cardiac cell model. Cardiovasc Res. 2009;81:703-12.
34. Smeets PJ, Teunissen BE, Willemsen PH, van Nieuwenhoven FA, Brouns AE, Janssen BJ, Cleutjens JP, Staels B, van der Vusse GJ, van Bilsen M. Cardiac hypertrophy is enhanced in ppar alpha-/- mice in response to chronic pressure overload. Cardiovasc Res. 2008;78:79-89. (Pubitemid 351430958)
35. Linz W, Wohlfart P, Baader M, Breitschopf K, Falk E, Schafer HL, Gerl M, Kramer W, Rutten H. The peroxisome proliferatoractivated receptor-alpha (ppar-alpha) agonist, ave8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin. 2009;30:935-46.
36. Smeets PJ, de Vogel-van den Bosch HM, Willemsen PH, Stassen AP, Ayoubi T, van der Vusse GJ, van Bilsen M. Transcriptomic analysis of pparalpha-dependent alterations during cardiac hypertrophy. Physiol Genomics. 2008;36:15-23.
37. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ, Fruchart JC, Tedgui A, Haegeman G, Staels B. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative crosstalk with transcription factors nf-kappab and ap-1. J Biol Chem. 1999;274:32048-54.
38. Planavila A, Rodriguez-Calvo R, Jove M, Michalik L, Wahli W, Laguna JC, Vazquez-Carrera M. Peroxisome proliferatoractivated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;65: 832-41. (Pubitemid 40249728)